Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hannah R. Robinson"'
Publikováno v:
Advances in Oncology. 3:161-177
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d196c2fe74a1368e253b75b0f7b7f189
https://doi.org/10.1016/j.yao.2023.01.011
https://doi.org/10.1016/j.yao.2023.01.011
Publikováno v:
JAMA Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1223da00d6312755d7b3e65a0ba2912
https://doi.org/10.1001/jamaoncol.2023.1088
https://doi.org/10.1001/jamaoncol.2023.1088
Autor:
Eman L. Dadashian, Nakhle S. Saba, Sivasubramanian Baskar, Erika M. Cook, Hannah R. Robinson, Junpeng Qi, Christoph Rader, Adrian Wiestner, Inhye E. Ahn, Keyvan Keyvanfar, Chingiz Underbayev, Clare Sun, Sarah E. M. Herman, Cydney M. Nichols
The Bruton tyrosine kinase inhibitor ibrutinib induces high rates of clinical response in chronic lymphocytic leukemia (CLL). However, there remains a need for adjunct treatments to deepen response and to overcome drug resistance. Blinatumomab, a CD1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::304a4ea5bb468b219ebdaf51fb194790
https://europepmc.org/articles/PMC6073325/
https://europepmc.org/articles/PMC6073325/
Autor:
Inhye E. Ahn, Junpeng Qi, Adrian Wiestner, Sarah E. M. Herman, Christoph Rader, Erika M. Cook, Sivasubramanian Baskar, Hannah R. Robinson
Publikováno v:
Blood. 130:799-799
Kinase inhibitors such as ibrutinib have advanced treatment of chronic lymphocytic leukemia (CLL). However, there remains a need for adjunct treatments capable of deepening response or overcoming resistance to kinase inhibitors. CD19/CD3 bispecific a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52ea63d5c40044f9f43df7f98175ad4f
https://doi.org/10.1182/blood.v130.suppl_1.799.799
https://doi.org/10.1182/blood.v130.suppl_1.799.799